Verition Fund Management
KERX

Verition Fund Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Verition Fund Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-14,355
Closed -$186K – 697
2013
Q4 		$186K Buy
+14,355
New +$171K 0.03% 408

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Verition Fund Management's KERX Position: Q1 2014 in Review

Verition Fund Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2014, closing a stake of 14,355 shares — an estimated $186K sold.

Verition Fund Management first reported a position in KERX in Q4 2013 and held it in 1 quarter. The position peaked at $186K in Q4 2013. 150 funds tracked by Wall St. Rank hold KERX as of Q1 2014.

  • Verition Fund Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2014 after selling out during the quarter.
  • Verition Fund Management sold 14,355 Keryx Biopharmaceuticals Inc shares in Q1 2014, an estimated $186K.
  • Verition Fund Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and held it in 1 quarter.
  • Verition Fund Management's Keryx Biopharmaceuticals Inc position peaked at $186K in Q4 2013.
  • 150 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2014.

Based on Verition Fund Management's 13F filing for Q1 2014, filed 14 May 2014.